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Abstract
Introduction: Tamoxifen may occasionally precipitate serious and potentially life-threatening hypercalcemia.
However, to date, this has not been documented with aromatase inhibitors.
Case presentation: A 65-year-old Japanese woman with liver metastasis from breast cancer was admitted to our
hospital with vomiting, anorexia, fatigue, arthralgia, muscle pain and dehydration. She had started a course of
letrozole five weeks earlier. Our patient’s calcium level was 11.6 mg/dL. She was rehydrated and elcatonin was
administered. Our patient’s parathyroid hormone and parathyroid hormone-related protein levels were not
increased and a bone scintigram revealed no evidence of skeletal metastasis. After our patient’s serum calcium
level returned to within the normal range, letrozole was restarted at one-half of the previous dose (1.25 mg). There
were no episodes of hypercalcemia. However, 84 days after restarting letrozole, our patient again complained of
arthralgia and treatment was changed to toremifene. During these periods, repeated ultrasonograms revealed no
progression of liver metastasis.
Conclusion: To the best of our knowledge, this is the first case report of flare hypercalcemia after treatment with
letrozole in a patient with metastatic breast cancer.
Introduction
Flare reaction, a transient exacerbation of symptoms,
has been described primarily in breast cancer treatment
with tamoxifen and in prostate cancer following therapy
with luteinizing hormone-releasing hormone analogues
[1,2]. However, the association between a flare reaction
and aromatase inhibitors (AIs) has not been documen-
ted. We report a case of hypercalcemia that occurred 37
days after initiation of letrozole in a patient with liver
metastasis from breast cancer.
Case presentation
A 65-year-old Japanese woman was admitted to our
hospital one year ago with vomiting, anorexia, fatigue,
arthralgia, muscle pain, and dehydration (Figure 1). Our
patient had undergone a right mastectomy 30 years pre-
viously and received adjuvant chemoendocrine therapy
(doxifluridine and tamoxifen) without complications.
Five years after that surgery, she developed a tumor in
her liver and a needle biopsy revealed metastatic adeno-
carcinoma from breast cancer (estrogen-receptor posi-
tive, progesterone-receptor positive, Her2 negative).
Since then, our patient has been treated with taxanes
and capecitabine, followed by doxifluridine and medrox-
yprogesterone acetate. Using doxifluridine and medroxy-
progesterone acetate, she remained well and achieved a
complete response without an increase of carcinoem-
bryonic antigen (CEA) or carbohydrate antigen (CA) 15-
3 for eight years. However, three months before this
current admission, CEA and CA 15-3 had increased to
6.3 ng/mL (normal value < 5 ng/mL) and 30.6 IU/mL
(normal value < 23 IU/mL) respectively and an abdom-
inal ultrasonogram revealed recurrence of liver metasta-
sis. A computed tomography (CT) scan was normal.
Letrozole was initiated with alendronate (T score -2.8)
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pain and arthralgia. Two weeks after the onset of these
symptoms, the severity increased and our patient was
admitted to our hospital. Her serum calcium level was
11.6 mg/dL. She was rehydrated and elcatonin was
administered. Parathyroid hormone (PTH) and parathyr-
oid hormone-related protein (PTHrP) levels were not
increased and a bone scintigram, CT and thoracolumbar
survey revealed no evidence of skeletal metastasis. Intra-
venous bisphosphonate was not administered as our
patient had been undergoing dental treatment. She was
discharged when symptoms subsided on day 11. One
week later, after the completion of her dental treatment,
our patient was administered zoledronate for persistent
hypercalcemia. Thereafter, our patient was readmitted
due to hypocalcemia. After our patient’s serum calcium
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Figure 1 Changes in serum calcium level and tumor markers before and after flare hypercalcemia. The normal range of serum calcium
level was 8.4 mg/dL to 9.7 mg/dL (this was changed to 8.5 mg/dL to 10.2 mg/dL at midstream), and the calcium level was corrected with
albumin by a standard calculation.
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restarted at one-half dose (1.25 mg) with no reoccur-
rence of hypercalcemia. Unfortunately, 84 days after the
restart, letrozole was withheld due to intolerable arthral-
gia and our patient’s therapy was changed to toremifene.
Although she complained of mild arthralgia while on
toremifene, the symptom gradually subsided and she has
remained well. Repeated ultrasonograms revealed no
progression of liver metastasis. Our patient’sC E Aa n d
CA 15-3 have again increased to pretreatment levels but
have remained stable.
Discussion
A flare reaction was first observed during the treatment
of postmenopausal women with high-dose estrogen and
has been frequently documented with tamoxifen [1,3].
This reaction comprises two different manifestations:
tumor flare and flare hypercalcemia [2]. The former
includes an increase in swelling, erythema, itching, or
pain in soft-tissue metastasis, the development of new
lesions, an increase of tumor markers and an increase in
skeletal pain in patients with bone metastasis. Tumor
flare can be accompanied by flare hypercalcemia.
The distinction between spontaneous hypercalcemia
and flare hypercalcemia is sometimes difficult to ascer-
tain. Although both occur most often in patients with
widespread bone metastases [4,5], flare hypercalcemia
can be seen in patients without apparent bone involve-
ment [6,7], as in the case of our patient. Moreover, flare
hypercalcemia has a rapid onset that characteristically
occurs within several days of starting therapy; symptoms
are usually short-lived and serum calcium levels return
to normal when the offering agent is withdrawn. In con-
trast, spontaneous hypercalcemia is generally slow in
onset and, accordingly, symptoms develop gradually
[1,8]. In general, the following three criteria are used to
prove a causal relation between drug and symptom: the
symptom should develop after drug administration,
reverse when it is withdrawn, and be reinduced by
rechallenge [9]. In this respect, flare hypercalcemia
could meet two of these three criteria. Similar to other
reports of flare hypercalcemia [5,6,8-11], the third criter-
ion is not met in the case of our patient; however, the
temporary relation of the onset of hypercalcemia and
administration of letrozole strongly suggests a causal
role for the drug.
Our review of the literature did not reveal any descrip-
tion of flare hypercalcemia by AIs with the exception of
one report of tumor flare and tumor lysis syndrome by
letrozole. In a study by Zigrossi et al. [12], a 61-year-old
woman experienced tumor flare (pleural and pericardial
effusion) and tumor lysis syndrome on the second day of
letrozole administration and subsequently recovered
from critical condition, notwithstanding continuation of
letrozole. Tumor lysis syndrome is characterized by the
rapid death of neoplastic cells that develops soon after
effective therapy. The biochemical and clinical features of
this syndrome include hyperazotemia, hyperuricemia,
hyperkalemia, hypocalcemia, elevated lactate dehydro-
genase, hypotension and acute renal failure. The patient
in the study did not develop hypercalcemia.
The exact mechanism of flare hypercalcemia remains
uncertain, and it is believed that estrogenic properties of
tamoxifen may precipitate hypercalcemia in tamoxifen-
induced hypercalcemia. Although this does not account
for AIs, it is interesting to note that flare hypercalcemia
could occur in estrogen-receptor negative patients [9].
Thus, it might be plausible to consider that flare hyper-
calcemia is due to increased osteoclast activities and
bone resorption caused by the increased release of var-
ious factors from the tumor or host cells by the offend-
ing drug [7,11,13]. Importantly, normal PTH and/or
PTHrP levels in our patient exclude the possibility of
coexisting primary hyperparathyroidism and ectopic
secretion of PTH and/or PTHrP caused by tumor cells.
Another cause of hypercalcemia might include inappro-
priately increased production of 1, 25-hydroxyvitamin
D3 typically seen in patients with lymphomas or sarcoi-
dosis [7]. However, the vitamin D3 levels were not
assessed and CT and clinical findings did not suggest
the possibility of these conditions as a cause of flare
hypercalcemia in our patient.
It is difficult to predict and to prevent flare hypercalce-
mia, but life-threatening hypercalcemia should be treated
intensively by stopping the offending drug, rehydration
and bisphosphonate treatment [13,14]. As for rechallenge
of the offending drug, it is usually suggested that, if
necessary, tamoxifen be resumed temporarily at a lower
dosage in tamoxifen-induced hypercalcemia. This is
because tumor regression could occur after the flare
reaction subsides and the survival of patients with tamox-
ifen-induced hypercalcemia is reported to be longer than
that of patients with spontaneous hypercalcemia
[1,2,8,15]. This strategy also appears to apply to AIs [12].
Conclusion
Our experience suggests that AIs may precipitate serious
and potentially life-threatening hypercalcemia in the
early stages of treatment. If this occurs, AIs could be
restarted cautiously with therapeutic benefit. To our
knowledge, the association of hypercalcemia and AIs has
not been previously reported.
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